AstraZeneca Delegations Visit Biointron Shanghai R&D Center
Biointron2023-03-21
On March 21st, Biointron Biological Shanghai R&D Center welcomed AstraZeneca delegations Mark Cobbold, Margie Li, Hao Huang, and Yingjie Wu for an on-site visit. Biointron's CEO Steven Zha and International BD Director Boris Xu along with other team members were also present to welcome the delegation.
During this visit, we had the opportunity to discuss the progress of our current collaborative projects and laid a stronger foundation for further collaboration. AstraZeneca acknowledged the latest development in Biointron’s services, including antibody expression and production, VHH antibody discovery platform, single B cell screening platform, and antibody engineering technology.
At Biointron Biological, we appreciate AstraZeneca's partnership and support for our development. We will continuously explore the development of antibody discovery platforms and AI automation of scientific manufacturing.
We will also strive to provide consistently high-quality services to our customers, and empower the global pharmaceutical industry in antibody drug discovery!
In March 2024, Cyagen and Biointron officially signed off on their strategic partnership, forging an alliance in antibody drug development. This partnership aims to fully leverage the strengths of Cyagen's HUGO-Ab™ fully humanized mouse antibody discovery platform and Biointron&#
Biointron is proud to announce a strategic partnership with FatiAbGen, a leading biotechnology firm focused on antibody-based therapeutics. As the newly appointed Korean distributor for Biointron, FatiAbGen will be at the forefront of delivering Biointron’s products to the Korean market.
